Objectives: To identify the fosfomycin pharmacokinetic (PK)/pharmacodynamic (PD) index (fT .MIC , fAUC/MIC or fC max /MIC) most closely correlated with activity against Pseudomonas aeruginosa and determine the PK/PD target associated with various extents of bacterial killing and the prevention of emergence of resistance.
Introduction
Effective treatment of infections caused by MDR Gram-negative pathogens such as Pseudomonas aeruginosa is a major medical challenge.
1-3 P. aeruginosa, previously identified by the IDSA as one of the top six pathogens threatening healthcare systems, 4, 5 has now been categorized as a 'Serious' threat level by the US CDC. 6 With numerous intrinsic and acquired resistance mechanisms present in this organism, 7 antibiotic resistance across all P. aeruginosa infections emerges during therapy in up to 25% of cases and is associated with treatment failure in 50%-85% of patients and greater risk of mortality. 8, 9 With a shortage of new antibiotics with novel mechanisms of action in the drug discovery and development pipeline, 10 there is a growing need to optimize the use of older 'forgotten' antibiotics 11 to treat infections, including those caused by P. aeruginosa.
12
Fosfomycin is an older antibiotic exhibiting activity against many Gram-negative pathogens, including a significant subset of MDR P. aeruginosa strains. [13] [14] [15] Given that it is generally well tolerated, 16 fosfomycin has been suggested as a promising agent for managing infections caused by Gram-negative bacilli that are resistant to commonly used antibiotics. 17 Unfortunately the development of fosfomycin (first isolated from Streptomyces species in 1969) 18 occurred when drug development was conducted more or less on a trial-and-error basis. 19 Consequently, there is a dearth of knowledge on the pharmacokinetic (PK) and pharmacodynamic (PD) properties of fosfomycin required to optimize therapy. 20 This lack of established regimens specifically for complicated infections is a primary limitation to the use of fosfomycin and carries significant risks for patient outcomes, adverse events and resistance emergence. 13, 21 It has been recommended that exposure-response relationships for older antimicrobials, including fosfomycin, be urgently established. 17, 20 The determination of the relationship between bacterial killing and emergence of resistance with respect to PK/PD indices and the determination of PK/PD targets will assist in the design of rational dosing strategies for fosfomycin. Therefore, we utilized an in vitro PK/PD model (i) to identify the PK/PD index [i.e. the cumulative percentage of a 24 h period for which unbound concentrations exceed the MIC (fT .MIC ), the area under the unbound concentration-time curve to MIC ratio (fAUC/MIC) or the unbound maximal concentration to MIC ratio (fC max /MIC)] that best predicts bacterial killing of fosfomycin against P. aeruginosa; and (ii) to determine the magnitude of the predictive PK/PD index required to achieve various extents of bacterial killing and/or prevent the emergence or amplification of fosfomycin-resistant mutants.
Materials and methods

Antibiotics, bacterial isolates and MIC testing
Fosfomycin disodium (Lot 20131012, Waterstone Technology, Carmel, IN, USA) and glucose-6-phosphate (G6P; Lot SLBD7775V, Sigma-Aldrich, Castle Hill, NSW, Australia) were supplied by their respective manufacturers. Sterile stock solutions were prepared in Milli-Q water immediately prior to each experiment. Cation-adjusted Mueller-Hinton agar and CAMHB supplemented with 25 mg/L G6P per CLSI guidelines were used in all experiments. 22 Three fosfomycin-susceptible strains of P. aeruginosa were examined: reference strain ATCC 27853 (ATCC, Manassas, VA, USA) and two previously described MDR clinical isolates [CR 1005 (non-mucoid) and CW 7 (mucoid)]. 23 MDR was defined as non-susceptibility to at least one antimicrobial agent in three or more antimicrobial categories. 24 The MICs, determined in duplicate on separate days using agar dilution per CLSI guidelines, 22 were 8 mg/L for ATCC 27853, 32 mg/L for CR 1005 and 16 mg/L for CW 7. As breakpoints for fosfomycin against Pseudomonas spp. are currently lacking, we applied modified CLSI breakpoints for Escherichia coli with an MIC 64 mg/L considered susceptible and .64 mg/L resistant. 22 
Population analysis profiles
The possible presence of fosfomycin-resistant subpopulations within the predominant (susceptible) population at baseline was determined via population analysis profiles (PAPs) (inoculum $10 8 cfu/mL) for each strain as described previously. 23 Fosfomycin heteroresistance was defined as the presence within a fosfomycin-susceptible isolate (i.e. MIC 64 mg/L) of subpopulations able to grow on agar containing .64 mg/L fosfomycin. Random colonies were selected from fosfomycin-containing agar plates for repeated MIC testing to confirm the increased MICs.
Dynamic in vitro PK/PD model, fosfomycin dosing regimens and emergence of resistance A previously described dynamic in vitro PK/PD model 25 was used over 24 h to examine the PK/PD index that best predicts the antimicrobial response of fosfomycin. Prior to each experiment, strains were subcultured onto Mueller-Hinton agar (Media Preparation Unit) and incubated overnight at 35 C. One colony was then selected and grown overnight in 10 mL of CAMHB from which early log-phase growth was obtained. A 1 mL aliquot was then injected into each central compartment to yield a starting inoculum of $10 6 cfu/mL.
Both continuous infusion and intermittent dosing regimens were simulated as described previously, 25 with serial samples for viable cell counting and determination of fosfomycin concentrations collected aseptically as shown in Table 1 . For intermittent regimens an elimination half-life (t1 =2 ) of 4 h was simulated, approximating fosfomycin elimination in critically ill patients 26, 27 and healthy volunteers. 28, 29 Given that fosfomycin has negligible plasma protein binding, 30, 31 concentrations were assumed to constitute unbound fosfomycin. Viability counting was undertaken as previously described 23 and antibiotic carryover minimized by centrifuging all samples for 5 min at 10000 rpm with resuspension in prewarmed saline (37 C) . To additionally examine the presence of fosfomycin-resistant subpopulations at baseline (0 h) and following 24 h of treatment, PAPs were conducted on all isolates for a subset of experiments at these times on Mueller-Hinton agar containing G6P (25 mg/L) and fosfomycin at 32, 64, 128 and 256 mg/L.
Three intermittent dosing intervals (8, 12 and 24 h) with fC max varied across each schedule plus constant concentration (CC) regimens were examined (Table 1) . Dosing regimens were selected to maximally differentiate among the PK/PD indices under investigation (fAUC/MIC, fC max /MIC and fT .MIC ) and included a wide concentration range to allow exploration of the complete dose-response relationship from essentially no effect to maximum effect. Fosfomycin concentrations were determined using a previously published LC-MS/MS assay with minor modification. 32 The assay range was 1-500 mg/L; samples were diluted if the expected fosfomycin concentrations were higher than the upper limit of quantification.
Investigation of PK/PD indices
For each dosing regimen the %fT .MIC , fAUC/MIC, fC max /MIC and the area under the killing curve (AUC cfu ) of the time-course profile of bacterial numbers (cfu/mL from 0 to 24 h) were determined as described previously at both 1% and 10% MIC. 25 The log ratio area method, which mostly compensates for the bacterial loss from the model, 33 was used to quantify the killing effect (drug effect) chosen as the measure of efficacy (E) per the equation: E " log 10 [AUC cfu(treatment) /AUC cfu(growth control) ].
The relationship between killing effect (E) and each PK/PD index was analysed as described previously using a Hill equation with a baseline and an inhibitory effect, with the magnitude of the most predictive PK/PD index required to achieve 1 or 2 log 10 reduction in the area under the cfu/mL curve relative to growth control estimated from the E 0 , E max , EI 50 and c. 25 
Results
Baseline PAPs
Baseline PAPs are shown in Representative time-course profiles of bacterial numbers for each isolate, including the PAPs, are presented in Figure 3 . The initial inocula in the control and treatment compartments (mean + SD) were: 6.03 (n " 2) and 5.91+0.24 (n " 27) log 10 cfu/mL for ATCC 27853, 6.07+0.30 (n " 3) and 6.34+0.18 (n " 25) log 10 cfu/mL for CR 1005, and 6.35+0.12 (n " 4) and 6.01+0.15 (n " 30) log 10 cfu/mL for CW 7. After 24 h, bacterial numbers in the control compartments had increased to 8.1 (n " 2), 8.15+0.26 (n " 3) and 8.30+0.27 (n " 4) log 10 cfu/mL for ATCC 27853, CR 1005 and CW 7, respectively. The rate of initial bacterial killing against each isolate generally increased with increasing fosfomycin concentrations up to $10% MIC; further increases did not produce more rapid or extensive killing. With the majority of fosfomycin regimens, initial killing of no more than $3 log 10 cfu/mL occurred across the first 4-8 h for all isolates followed by regrowth close to control values at 24 h. In a small number of cases with very high-dose regimens [e.g. fC max of 750 mg/L and 1500 mg/L every 12 h against ATCC 27853 (Figure 3 , left-hand panel)], regrowth remained below the initial inoculum at 24 h. Maximum bacterial killing achieved against ATCC 27853 was 3.0 log 10 cfu/mL using an fC max of 1500 mg/L administered every 12 h. The equivalent values and regimens for CR 1005 and CW 7 were 3.1 log 10 cfu/mL with an fC max of 750 mg/L every 12 h and 3.2 log 10 cfu/mL with two regimens, fC max of 1500 mg/L every 12 h and 500 mg/L as a CC, respectively.
For the subset of experiments that included PAPs, no fosfomycin-resistant colonies for any strain were detected immediately prior to the commencement of therapy at the starting inoculum of $10 6 cfu/mL ( Figure 3 , right-hand panels). For the growth controls, PAPs following 24 h of incubation indicated the presence of resistant subpopulations in all three strains; growth at this time was $10 8-8.5 cfu/mL. The proportion of resistant colonies growing on plates containing fosfomycin at 128 mg/L at 24 h was 1.87%10 #6 , 1.02%10 #4 and 1.81%10 #6 for ATCC 27853, CR 1005 and CW 7, respectively. These proportions were similar to those observed with the baseline PAPs (inoculum $10 8 cfu/mL). With the exception of the fC max 32 mg/L 12 h regimen against CW 7 (in which the proportion of resistant colonies at 24 h was 3.33%10 
Relationships between bacterial killing and PK/PD indices
The relationships between killing effect and fAUC/MIC, fC max /MIC and fT .MIC are shown in Figure 4 . At 1% and 10 % MIC the PK/PD index that best predicted efficacy was fAUC/MIC (R 2 " 0.80; Figure 4 , top row). A poorer relationship existed between the Results from a previous study. Bilal et al.
killing effect and fC max /MIC, for which greater scatter and systemic deviations from the curve fit were observed (R 2 " 0.71; Figure 4 , middle row). No relationship was observed for fT .MIC at 1% MIC (Figure 4c ), but one was found at 10 % MIC (R 2 " 0.70; Figure 4f ). The magnitudes of the fAUC/MIC indexes required for 1 and 2 log 10 reduction in the area under the cfu/mL curve relative to growth control for each strain were 489 and 1024, respectively.
Discussion
Oral fosfomycin (fosfomycin tromethamine) is currently indicated for treatment of uncomplicated urinary tract infections caused by E. coli and Enterococcus faecalis in women. 34 However, the parenteral (disodium) formulation is increasingly used to treat systemic infections caused by MDR organisms, including P. aeruginosa.
35-37
Unfortunately, the information required to optimize dosing regimens using exposure-response relationships is not available. It has therefore been suggested that establishing the exposureresponse relationships for fosfomycin for both efficacy and resistance selection-which are often distinctly different-be made a priority. 20 We sought to determine the predictive performance of potential PK/PD indices with respect to bacterial killing and the emergence of resistance against P. aeruginosa, including MDR isolates.
We have previously reported maximal bacterial killing of $3 log 10 cfu/mL followed by rapid regrowth against P. aeruginosa ATCC 27853 in a 24 h PK/PD model using once-daily dosing (fC max , 1000 mg/L). 23 Similar maximal killing was recently shown for the same strain using static time-kill studies (C max , 128 mg/L) and a tissue-cage infection model. 38 This maximal level of killing is almost identical to that achieved here against the same reference strain and two additional MDR clinical isolates with dosing regimens providing a much greater exposure to fosfomycin (e.g. fC max 1000 mg/L every 12 h or fC max 3000 mg/L every 24 h). Importantly, near-complete replacement of susceptible with resistant subpopulations occurred with virtually all regimens. Although fosfomycin-resistant colonies were not detected immediately prior to commencement of therapy in the dose-fractionation studies (inoculum $10 6 cfu/mL), $2-3 log 10 cfu/mL of resistant colonies growing on agar containing 256 mg/L fosfomycin were present in the baseline PAPs (inoculum $10 8 cfu/mL). Thus, it is highly likely that resistant subpopulations were present at the commencement of therapy in the dose-fractionation studies but were simply not detected at the lower inoculum. The rapid regrowth observed following commencement of fosfomycin administration was driven, at least in part, by amplification of these pre-existing, highly fosfomycin-resistant subpopulations. This is similar to what we observed previously against P. aeruginosa at much lower fosfomycin exposures [maximum AUC 0-24 of 5680, 2840 mgÁh/L (fC max of 1000 and 500 mg/L administered every 24 h)]. 23 However, even an AUC 0-24 of 25247 mgÁh/L (fC max of 2500 mg/L administered every 12 h) in the present study could not suppress the emergence of resistance; this is much greater than achieved in patients with standard dosing regimens (typically 4-8 g intravenously every 8 h for serious systemic infections) in which fC max typically ranges from 400 to 1000 mg/L. 26, 31, 32, 39 Very few studies have previously examined the emergence of fosfomycin resistance. Using a hollow-fibre infection model (half-life, 4 h; initial inoculum, $1%10 6 cfu/mL) and a single clinical isolate of E. coli, Docobo-Pérez et al. 40 simulated human-like These results indicate that at least for this single isolate of E. coli resistance suppression is achievable. Given that both the 8 g/8 h and 24 g/24 h regimens eradicated the entire population, the authors concluded that the fAUC/MIC was the dynamic index best linked to resistance suppression. VanScoy et al. 41 were similarly able to suppress bacterial regrowth and the emergence of fosfomycin-resistant subpopulations of a heteroresistant E. coli reference strain with regimens containing !1 g of fosfomycin administered every 6 h. However, even with these dosing regimens the total population was not eradicated. With regimens containing 0.5 g administered every 6 h, rapid bacterial regrowth with amplification of fosfomycinresistant subpopulations occurred such that the latter completely replaced the total population. They obtained similar results against the same strain in dose-fractionation studies (discussed below) in which emergence of resistant subpopulations, often completely dominating the total population, occurred with lower-dose regimens but was suppressed or even eliminated completely with higher-dose regimens. The relationship between fosfomycin dose and the emergence of resistant subpopulations matched an inverted-U-shaped function, described previously with other antibiotics, including against P. aeruginosa.
42,43
Using single reference strains of E. coli and P. aeruginosa (ATCC 27853), Pan et al. 38 reported selective enrichment of resistant subpopulations (growing on agar containing fosfomycin at 4, 8 and 16% MIC) for both isolates across a specific concentration range, but no development of fosfomycin resistance at a higher Bilal et al.
concentration. For P. aeruginosa, enrichment occurred with concentrations of 16-64 mg/L for time-kill studies, with resistance suppression occurring at 128 mg/L; a similar result was achieved with in vivo tissue-cage experiments (24 h dosing with a maximum achieved concentration of $300 mg/L). To the best of our knowledge this is the only report indicating suppression of resistance against P. aeruginosa with fosfomycin monotherapy. This is an interesting and unexplained result given the extremely high initial PK/PD of fosfomycin against Pseudomonas aeruginosa JAC inoculum ($10 9 cfu/mL). We have previously shown in static timekill studies a pronounced inoculum effect for fosfomycin against three strains of P. aeruginosa, including ATCC 27853, with bacterial killing essentially eliminated at an inoculum of $10 8 cfu/mL across a concentration range of 1-1024 mg/L; highly resistant subpopulations were enriched with all but the lowest concentrations used. 23 Given our previous observations of a near-complete lack of activity with monotherapy at a high inoculum, we chose a lower inoculum ($10 6 cfu/mL) for the present study. However, extremely high exposures in the present study (up to an fC max of 3000 mg/L) with a lower starting inoculum were similarly unable to suppress amplification of resistant subpopulations, even with the loss of some bacteria from the system; bacterial loss is a limitation of onecompartment models. This situation would only be made worse if a shorter half-life, which would reduce bacterial killing even further, were to be used; half-lives of 2-3 h have been reported in some critically ill patients. 44, 45 Regardless of resistance emergence, absolute bacterial numbers in the study by Pan et al. 38 never dropped below $5-6 log 10 cfu/mL. That study notwithstanding, although increasing fosfomycin exposures may prevent or limit the emergence of resistance against other organisms such as E. coli, such a relationship does not appear to exist against P. aeruginosa. Indeed, we previously found that all of the 14 P. aeruginosa isolates examined (MIC range: 1-64 mg/L) contained resistant subpopulations, 23 and that only moderate bacterial killing is achievable even with supra-therapeutic exposures (maximum killing of $3 log 10 cfu/ mL). Therefore, against P. aeruginosa, treatment failure with fosfomycin monotherapy would appear likely even considering the potential added effect of the immune system, 46 with monotherapy regimens serving only to amplify pre-existing and highly resistant subpopulations. This situation is compounded by the fact that resistance to fosfomycin in P. aeruginosa appears to come with no apparent fitness cost. 14, 47, 48 The difference in resistance suppression between P. aeruginosa and E. coli may be due to differences in the transport systems required for fosfomycin entry into the cells. E. coli contains two transport systems, the glycerol-3-phosphate (GlpT) and a hexose phosphate (UhpT), whereas P. aeruginosa contains only GlpT. 49, 50 Thus only a single mutation is required in P. aeruginosa to prevent fosfomycin entry and render the organism resistant, whereas in E. coli two mutations would be required. 47, 48, [51] [52] [53] Only two previous studies have purported to examine the exposure-response relationships for bacterial killing of fosfomycin against any organisms. VanScoy et al. 41 used a one-compartment PK/PD model similar to ours to examine bacterial killing and resistance emergence against one reference strain and two clinical isolates of E. coli. Experiments were conducted over 24 h (starting inoculum $1%10 6 cfu/mL) and simulated a fosfomycin half-life of 2 h. Three regimens with intermittent administration every 6, 8 and 12 h, as well as a continuous-infusion regimen, were examined, with each providing the same total daily fosfomycin exposure (as measured by the AUC 0-24 ). The authors concluded that fosfomycin activity was most likely linked to fAUC/MIC (R 2 " 0.76), although there was also a strong correlation with fC max /MIC (R 2 " 0.62); there was a poor relationship between bacterial killing and fT .MIC (R 2 " 0.42). However, it was noted that given the majority of fT .MIC values were 100%, the PK/PD relationship based on this index could not be adequately explored. Lepak et al. 54 used the neutropenic murine thigh infection model to examine the PK/PD activity of fosfomycin against five strains of E. coli, three of Klebsiella pneumoniae and two of P. aeruginosa. Although they determined that the PK/PD index best correlated with activity against these organisms was the AUC/MIC (R 2 " 0.70; protein binding was not stated), dose-fractionation was only conducted on a single strain of E. coli; for K. pneumoniae and P. aeruginosa, only increasing doses administered every 3 h were used, with the index determined for E. coli assumed to also apply to these organisms. Our dose-fractionation study employed the largest range of fosfomycin concentrations (fC max range: 6.25-3000 mg/L) and dosing regimens (30 different regimens) used against any organism and is the first to specifically use a dose-fractionation design to examine the PK/PD index driving bacterial activity and the emergence of resistance for fosfomycin against P. aeruginosa. In agreement with the E. coli studies of VanScoy et al. 41 and Lepak et al., 54 bacterial killing was most closely correlated with fAUC/MIC. Although we have previously shown using both MDR and non-MDR isolates of P. aeruginosa that bacterial killing by fosfomycin against this organism is time dependent, 23 we were unable to find a relationship between activity and fT .1%MIC . This may be explained by a large number of the dosing regimens having a fT .1%MIC of 100%. To account for this we also analysed each index at 10% MIC. Although a relationship was present between activity and fT .10%MIC (Figure 4f ), the fAUC/MIC nevertheless remained the index most closely associated with activity. This is the first study to utilize a dose-fractionation design to investigate the relationship between PK/PD indices and bacterial killing for fosfomycin against P. aeruginosa. The fAUC/MIC was most closely correlated with bacterial killing. No fosfomycin exposures, including exposures well above those that are clinically achievable in plasma following intravenous administration, were able to suppress the emergence of resistant subpopulations. Our results suggest that for systemic infections involving P. aeruginosa, fosfomycin monotherapy will be ineffective.
